# US 2025/0320207 A1 · Ketal Protected Intermediate for Sonrotoclax and Preparation Method Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0320207 A1
- Document ID: US20250320207A1
- Status: Published application
- Kind: A1
- Application number: 19/250,658
- Filed: 2025-06-26
- Published: 2025-10-16
- Earliest claimed: 2022-12-27
- Assignees: BeOne Medicines I GmbH
- Applicants: BeOne Medicines I GmbH
- Inventors: Zhengfeng Li; Tao Zhang; Liwen Xu; Juntao Liu; Qun Jiang
- Web page: https://patentgrep.com/patent/US20250320207A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07D 221/20: Spiro-condensed ring systems
- C07D 491/113: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compounds of Formula (I) having protective group of ketal used as intermediates for preparing 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-N-((4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrophenyl) sulfonyl)-4-(2-((S)-2-(2-isopropylphenyl) pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzamide (Sonrotoclax), and processes for preparing compounds of Formula (I), especially 1,5-dioxa-11-azadispiro[5.1.5.1]tetradecane.

## Claims

### Claim 1

A compound selected from:
1
2
3
4
or a salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is
or a salt thereof.

### Claim 3 (depends on 1)

The compound of claim 1, wherein the compound is
or a salt thereof.

### Claim 4 (depends on 1)

The compound of claim 1, wherein the compound is
or a salt thereof.

### Claim 5 (depends on 1)

The compound of claim 1, wherein the compound is
or a salt thereof.

### Claim 6

A method of making a compound of Formula (SII),
or a salt thereof, comprising reacting a compound of Formula (I):
or a salt thereof with a compound of Formula (SI):
in the presence of a base,
wherein
at each of its occurrences, R is independently C2-6alkyl or C3-6cycloalkyl, wherein each of said C2-6alkyl or C3-6cycloalkyl is optionally substituted with halogen, —C1-8alkyl, —C2-8alkenyl, —C2-8alkynyl, —C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, C6-C12aryl, 5- to 12-membered heteroaryl, oxo, —CN, —NO2, —C(═O)R1a, —C(═O)OR1a, —OC(═O)R1a, —OR1a, —SO2R1a, —SR1a, —NR1aR1b, —C(═O)NR1aR1b, —OC(═O)NR1aR1b, —NR1aC(═O)NR1bR1c or —NR1aC(═O)R1b; or
two R together with the two oxygen atoms to which each is attached and the intervening carbon, form a 5- to 12-membered ring, said ring is optionally substituted with at least one substituent selected from halogen, —C1-8alkyl, —C2-8alkenyl, —C2-8alkynyl, —C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, C6-C12aryl, 5- to 12-membered heteroaryl, oxo, —CN, —NO2, —C(═O)R1a, —C(═O)OR1a, —OC(═O)R1a, —OR1a, —SO2R1a, —SR1a, —NR1aR1b, —C(═O)NR1aR1b, —OC(═O)NR1aR1b, —NR1aC(═O)NR1bR1c or —NR1aC(═O)R1b;
at each of its occurrences, R1a, R1b and R1c are each independently selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, -haloC1-6alkyl or -haloC3-6cycloalkyl;
X is halogen; preferably, X is F, Cl, Br, or I; more preferably, X is F; and
R1 is C1-6alkyl, or C3-6cycloalkyl, wherein each of said C1-6alkyl or C3-6cycloalkyl is optionally substituted with halogen, —C1-8alkyl, —C2-8alkenyl, —C2-8alkynyl, —C3-C8cycloalkyl, 3- to 8-membered heterocyclyl, C6-C12aryl, 5- to 12-membered heteroaryl, oxo, —CN, —NO2, —C(═O)R1a, —C(═O)OR1a, —OC(═O)R1a, —OR1a, —SO2R1a, —SR1a, —NR1aR1b, —C(═O)NR1aR1b, —OC(═O)NR1aR1b, —NR1aC(═O)NR1bR1c or —NR1aC(═O)R1b;
at each of occurrences, R1a, R1b and R1c are each independently selected from hydrogen, C1-6alkyl, C3-6cycloalkyl, -haloC1-6alkyl or -haloC3-6cycloalkyl.

### Claim 7 (depends on 6)

The method of claim 6, wherein the base is 1,8-Diazabicyclo(5.4.0) undec-7-ene (DBU).

### Claim 8 (depends on 6, 7)

The method of claim 6 or 7, comprising reacting the compound of Formula (I) and the compound of Formula (SII) at a temperature between about 65° C. and about 75° C., or at a temperature of about 65° C., about 70° C., or about 75° C.

### Claim 9 (depends on 6, 7, 8)

The method of any one of claims 6-8, further comprising reacting the compound of Formula (SII) with an acid or a base to provide a compound of Formula (SIII),
or a salt thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the acid is HCl, or the base is NaOH.

### Claim 11 (depends on 9, 10)

The method of claim 9 or 10, further comprising reacting the compound of Formula (SIII), or a salt thereof, with (S)-2-(2-isopropylphenyl) pyrrolidine, or a salt thereof, to provide a compound of Formula (SIV)
or a salt thereof.

### Claim 12 (depends on 11)

The method of claim 11, comprising reacting the compound of Formula (SIII), or a salt thereof, with (S)-2-(2-isopropylphenyl) pyrrolidine, or a salt thereof, in the presence of NaBH(OAc)3.

### Claim 13 (depends on 11, 12)

The method of claim 11 or 12, comprising reacting the compound of Formula (SIII), or a salt thereof, with (S)-2-(2-isopropylphenyl) pyrrolidine, or a salt thereof, at a temperature less than about 30° C.

### Claim 14 (depends on 11, 12, 13)

The method of any one of claims 11-13, further comprising reacting the compound of Formula (SIV), or a salt thereof, with 4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide, to provide Sonrotoclax,
or a salt thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the reaction happens in the presence of EDCI and DMAP.

### Claim 16 (depends on 14, 15)

The method of claim 14 or 15, further comprising reacting the compound of Formula (SIV), or a salt thereof, with an acid or a base, to provide (S)-2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-isopropylphenyl) pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzoic acid
or a salt thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the acid is HCl, or the base is NaOH.

### Claim 18 (depends on 16, 17)

The method of claim 16 or 17, further comprising reacting(S)-2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-isopropylphenyl) pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzoic acid
or a salt thereof, with 4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide, to provide Sonrotoclax,
or a salt thereof.

### Claim 19 (depends on 16, 17, 18)

The method of any one of claims 16-18, comprising reacting(S)-2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(2-(2-(2-isopropylphenyl) pyrrolidin-1-yl)-7-azaspiro[3.5]nonan-7-yl)benzoic acid
or a salt thereof, with 4-((((1r,4r)-4-hydroxy-4-methylcyclohexyl)methyl)amino)-3-nitrobenzenesulfonamide in the presence of EDCI and DMAP.

### Claim 20 (depends on 14)

A method for preparing a pharmaceutical composition comprising Sonrotoclax, comprising mixing Sonrotoclax with a pharmaceutically acceptable excipient, wherein Sonrotoclax is prepared according to the method of claim 14.

### Claim 21 (depends on 18)

A method for preparing a pharmaceutical composition comprising Sonrotoclax, comprising mixing Sonrotoclax with a pharmaceutically acceptable excipient, wherein Sonrotoclax is prepared according to the method of claim 18.

### Claim 22 (depends on 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

A pharmaceutical composition comprising sonrotoclax or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient, wherein sonrotoclax is prepared according to the method of any one of claims 6-19.
